NNNN (Anbio Biotechnology) ROE % Adjusted to Book Value: 0.41% (As of Dec. 2025)


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $12.46
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology ROE % Adjusted to Book Value?

Anbio Biotechnology NNNN +2.88% 24 ROE % Adjusted to Book Value is 0.41% as of Dec. 2025. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Anbio Biotechnology's ROE % for the quarter that ended in Dec. 2025 was 18.06%. Anbio Biotechnology's PB Ratio for the quarter that ended in Dec. 2025 was 43.77. Anbio Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 0.41%.

Anbio Biotechnology ROE % Adjusted to Book Value Related Terms

Anbio Biotechnology ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology ROE % Adjusted to Book Value Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00 0.62

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.67 0.41

NNNN vs ANGO, OSUR, UTMD: ROE % Adjusted to Book Value Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anbio Biotechnology ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's ROE % Adjusted to Book Value falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology ROE % Adjusted to Book Value Calculation

Anbio Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=27.05% / 43.77
=0.62%

Anbio Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=18.06% / 43.77
=0.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.41% mean?
Anbio Biotechnology (NNNN) has a ROE % Adjusted to Book Value of 0.41% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's ROE % Adjusted to Book Value too high?
Anbio Biotechnology's current ROE % Adjusted to Book Value is 0.41%. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's ROE % Adjusted to Book Value compare to ANGO and OSUR?
Anbio Biotechnology's ROE % Adjusted to Book Value of 0.41% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current ROE % Adjusted to Book Value is 0.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current ROE % Adjusted to Book Value of 0.41%. The current ROE % Adjusted to Book Value is 0.41%. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current ROE % Adjusted to Book Value is 0.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.46
Price